Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 OXiGENE In-Licenses Rights to Cancer Program | Contract Pharma

What are you searching for?

Sign in
Breaking News

OXiGENE In-Licenses Rights to Cancer Program

To develop Zybrestat to treat carcinoid syndrome

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

OXiGENE, Inc. entered a worldwide agreement to license Angiogene Pharmaceuticals’ vascular disrupting agent (VDA) program for neuroendocrine cancers, focused on carcinoid syndrome. OXiGENE plans to develop Zybrestat to treat carcinoid syndrome associated with metastatic cancer and neuroendocrine tumors. OXiGENE expects to conduct a Phase II study in persistent carcinoid syndrome, with the potential to advance to a registration clinical program.
 
“In-licensing this intellectual property and other assets from Angiogene is strategically important for OXiGENE, providing the potential to significantly expand the commercial opportunity and patent protection for Zybrestat,” said Dr. Peter Langecker, OXiGENE’s chief executive officer. “OXiGENE has contemplated developing Zybrestat in carcinoid syndrome for some time, given the compelling scientific basis for using a VDA to disrupt blood flow to induce tumor necrosis and reduce production of well-validated biologic mediators, such as serotonin, which are associated with the most severe, debilitating symptoms of this disease.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics